[Dengue shock syndrome: decoding the pathophysiology].
Considered as major human arbovirosis, dengue occurs in several clinical forms. Some forms can lead to fatal complications such as dengue shock syndrome. This hypovolemic shock cannot be predicted and specific curative treatments are still lacking, and thus management of patients with dengue is difficult. The purpose of this review is to describe state-of-the-art of the knowledge on the pathophysiology of shock syndrome and to highlight the interest of high-content screening methods in translational approaches between research and medicine for investigation of individual response during dengue shock syndrome.
Devignot
S
S
Institut de Recherche Biomédicales des Armées, Antenne de Marseille (IMTSSA), Unité de Virologie Tropicale, France.
Tolou
H
H
Couissinier-Paris
P
P
D015415:Biomarkers / Q000097:blood; D018946:Chemokine CCL5 / Q000097:blood; D016207:Cytokines / Q000097:blood; D003716:Dengue Virus / Q000302:isolation & purification*; D003906:Developing Countries; D004730:Endothelium, Vascular / Q000503:physiopathology*; D019317:Evidence-Based Medicine; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D011159:Population Surveillance; D012307:Risk Factors; D019595:Severe Dengue / Q000175:diagnosis* / Q000276:immunology / Q000503:physiopathology* / Q000517:prevention & control / Q000628:therapy; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D015415:Biomarkers; D018946:Chemokine CCL5; D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha